DOCETBICIN 80 - Docetaxel

DOCETBICIN 80 – Docetaxel

Docetaxel 80 mg

Exporter, Distributor Drop shipper to Russia, Brazil, Colombia, Latin America And East Asia

Docetbicin 80 contains Docetaxel 80 mg, a taxane-based anticancer medication used in the treatment of various cancers, including breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head & neck cancers. It works by inhibiting cancer cell division and growth, making it an important component of established chemotherapy treatment protocols.

Contain

Docetaxel 80 mg

Strength

80 mg

Packaging

Combipack (Drug Vial + Solvent Vial)

Category

Categories:

Manufacturer

Baker & Davis Private Limited

Brand

Docetbicin

SEND US A MESSAGE

    CONTACT INFORMATION

    501, EAST BAY, BAYVUE, DR M B VELKAR MARG,
    KALBADEVI, MUMBAI-400002.

    +91 96531 13180

    sales@vinixbiopharma.com

    Do you have questions about how we can help your company? Send us an email and we’ll get in touch shortly.

    Product Overview

    DOCETBICIN 80 contains Docetaxel, a widely used taxane-based chemotherapeutic agent indicated for the treatment of various solid tumors. It is an essential component of modern oncology care and is commonly incorporated into established chemotherapy regimens for the management of multiple cancer types. With its proven clinical efficacy and well-established therapeutic profile, Docetaxel plays a vital role in helping healthcare professionals provide effective and comprehensive cancer treatment.

    Administered under the supervision of qualified oncology specialists, DOCETBICIN 80 is extensively used in hospitals, oncology centers, and specialized healthcare facilities worldwide. The medicine may be prescribed as a single-agent therapy or in combination with other anticancer medications depending on the patient’s diagnosis, disease stage, and treatment objectives. Its broad therapeutic applications make it a trusted option in contemporary oncology practice.


    How It Works

    Docetaxel works by stabilizing microtubules within cancer cells and preventing their normal breakdown during cell division. This action interferes with the mitotic process, preventing cancer cells from multiplying and ultimately leading to programmed cell death. By targeting rapidly dividing malignant cells, Docetaxel helps control tumor growth and supports effective cancer management.


    Therapeutic Applications

    DOCETBICIN 80 may be prescribed as part of treatment protocols for:

    • Breast Cancer
    • Non-Small Cell Lung Cancer (NSCLC)
    • Prostate Cancer
    • Gastric Cancer
    • Head and Neck Cancers
    • Advanced Solid Tumors
    • Other oncology indications as determined by the treating oncologist

    The medicine is frequently incorporated into combination chemotherapy regimens to improve therapeutic outcomes and support comprehensive cancer care.


    Key Benefits

    • Taxane-based anticancer therapy.
    • Widely used in established oncology treatment protocols.
    • Supports the treatment of multiple solid tumors.
    • Helps inhibit cancer cell growth and proliferation.
    • Suitable for monotherapy and combination chemotherapy regimens.
    • Manufactured under stringent pharmaceutical quality standards.

    Quality Commitment

    Vinix Biopharma is committed to delivering high-quality oncology products that meet stringent pharmaceutical standards. DOCETBICIN 80 is manufactured under controlled production environments and undergoes comprehensive quality assurance procedures to ensure safety, consistency, and reliability. Every batch is carefully tested to maintain product integrity and support effective patient care.


    Storage Information

    Store according to the instructions provided on the product label. Protect from excessive heat, direct sunlight, and moisture. Keep out of reach of children.


    Disclaimer

    DOCETBICIN 80 should be administered only under the supervision of qualified oncology specialists and trained healthcare professionals. Dosage and treatment schedules should be determined by the treating physician based on the patient’s medical condition, clinical assessment, and approved treatment guidelines.